Synthesis and biological evaluation of distamycin analogues - New potential anticancer agents

Archiv der Pharmazie

Volumn 342, Issue 2, 2009, Pages 87-93

  Drozdowska, Danuta ^a   Rusak, Malgorzata ^a   Miltyk, Wojciech ^a   Midura Nowaczek, Krystyna ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Cytotoxic activity; Distamycin analogue; DNA binding; DNA topoisomerase; Nticancer activity

Indexed keywords

ANTINEOPLASTIC AGENT; DISTAMYCIN A; DISTAMYCIN A DERIVATIVE; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; N,N BIS (3 AMINO PHENYL) ISOPHTHALAMIDE; N,N BIS (3 AMINO PHENYL) TEREPHTHALAMIDE; N,N BIS (5 AMINO PYRIDIN 2 YL) ISOPHTHALAMIDE; N,N BIS (5 AMINO PYRIDIN 2 YL) TEREPHTHALAMIDE; N,N BIS THIAZOL 2 YL ISOPHTHALAMIDE; N,N BIS THIAZOL 2 YL TEREPHTHALAMIDE; N,N DI PYRIDIN 2 YL ISOPHTHALAMIDE; N,N DI PYRIDIN 2 YL TEREPHTHALAMIDE; PLASMID DNA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DRUG DNA BINDING; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; STAINING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISTAMYCINS; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 62549110423     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200800122     Document Type: Article

References (17)

1. M. Palumbo, Advances in DNA Sequence-Specific Agents, JAI Press Inc., London 1998.
2. P. G. Baraldi, A. Bovero, F. Fruttarelo, D. Preti, et al., Med. Res. Rev. 2004, 24, 475 - 528.
3. U. Pindur, M. Jansen, T. Lemster, Curr. Med. Chem. 2005, 12, 2805-2847.
4. M. L. Kopka, C. Yoon, D. Goodsell, P. Pjura, R. E. Dickerson, Proc.Natl.Acad.Sci.U.SA. 1985, 82,1376-1380.
5. P. B. Dervan, Bioorg. Med. Chem. 2001, 9, 2215-2235.
6. D. Bartulewicz, K. Bielawski, A. Bielawska, Arch. Pharm Pharm. Med. Chem. 2002, 9, 422 -426.
7. A. PuCḱowska., K. Bielawski, A. Bielawska, A. RóZ̃ ański, Acta Biochim. Pol. 2002, 49, 177-183.
8. K. Bielawski, A. Bielawska, D. Bartulewicz, A. RóZ̃ań ski, ActaPol. Pharm. 2000, 57, 110-112.
9. K. Bielawski, A. Bielawska, D. Bartulewicz, A. RoZanski, Acta Biochim. Pol. 2000, 47, 855 -866.
10. D. Bartulewicz, K. Bielawski, A. Bielawska, A. RóZ̃ań ski, Eur. J. Med. Chem. 2001, 36, 461-467.
11. A. Markowska, A. Róz̃ański, S. Wolczyński, K. Midura-Nowaczek, Il Farmaco 2002, 57,1019-1023.
12. T. C. Jenkins in Drug-DNA Interactions Protocols, Methods in Molecular Biology, (Ed.: K. R. Fox), Humana Press, Totowa, NJ, USA, 1997, 90, 195.
13. R. C. Duke, J.J. Cohen, Curr. Protoc. Immunol. 1992,17,1 -6.
14. U. Beyer, T. Roth, P. Schumacher, G. Maier, et al., J. Med. Chem. 1998, 41, 2701-2708.
15. B. S. Reddy, S. K. Sharma, J. W. Lown, Curr. Med. Chem. 2001, 8, 475 -508.
16. S. Neidle, Nat. Prod. Rep. 2001,18, 291-309.
17. M. Gniazdowski, M. Czyz, Acta Biochim. Pol. 1999, 46, 255-262.